Cargando…
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib
As new treatment approaches, both immunotherapy and targeted treatments have been used in the clinical treatment of cancers. These therapies are different from traditional surgery, chemotherapy and radiotherapy. Use of a combination of immunotherapy and targeted treatments may improve tumor clearanc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175151/ https://www.ncbi.nlm.nih.gov/pubmed/28000738 http://dx.doi.org/10.1038/srep39598 |
_version_ | 1782484604875177984 |
---|---|
author | Gao, Ningning Zhong, Jingjing Wang, Xiaodong Jin, Zhenchao Li, Wang Liu, Yu Diao, Yuwen Wang, Zhulin Jiang, Wenqi Jin, Guangyi |
author_facet | Gao, Ningning Zhong, Jingjing Wang, Xiaodong Jin, Zhenchao Li, Wang Liu, Yu Diao, Yuwen Wang, Zhulin Jiang, Wenqi Jin, Guangyi |
author_sort | Gao, Ningning |
collection | PubMed |
description | As new treatment approaches, both immunotherapy and targeted treatments have been used in the clinical treatment of cancers. These therapies are different from traditional surgery, chemotherapy and radiotherapy. Use of a combination of immunotherapy and targeted treatments may improve tumor clearance. We investigated the feasibility of combining tyrosine kinase inhibitors (TKIs, targeted drugs) and SZU-101 (a novel TLR7 agonist synthesized by our laboratory). Thirteen different TKIs were combined with or without SZU-101 and studied to determine their effects on immunocytes. On the basis of the distinctive results, lapatinib and sunitinib were selected for further tumor-inhibition investigation and determination of the underlying mechanism. Interestingly, we found lapatinib to work better with SZU-101, enhancing tumor clearance in vivo, without affecting the TLR7-NF-κB pathway activated by the TLR7 agonist in mouse spleen lymphocytes and bone marrow dendritic cells (BMDCs). |
format | Online Article Text |
id | pubmed-5175151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51751512016-12-28 Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib Gao, Ningning Zhong, Jingjing Wang, Xiaodong Jin, Zhenchao Li, Wang Liu, Yu Diao, Yuwen Wang, Zhulin Jiang, Wenqi Jin, Guangyi Sci Rep Article As new treatment approaches, both immunotherapy and targeted treatments have been used in the clinical treatment of cancers. These therapies are different from traditional surgery, chemotherapy and radiotherapy. Use of a combination of immunotherapy and targeted treatments may improve tumor clearance. We investigated the feasibility of combining tyrosine kinase inhibitors (TKIs, targeted drugs) and SZU-101 (a novel TLR7 agonist synthesized by our laboratory). Thirteen different TKIs were combined with or without SZU-101 and studied to determine their effects on immunocytes. On the basis of the distinctive results, lapatinib and sunitinib were selected for further tumor-inhibition investigation and determination of the underlying mechanism. Interestingly, we found lapatinib to work better with SZU-101, enhancing tumor clearance in vivo, without affecting the TLR7-NF-κB pathway activated by the TLR7 agonist in mouse spleen lymphocytes and bone marrow dendritic cells (BMDCs). Nature Publishing Group 2016-12-21 /pmc/articles/PMC5175151/ /pubmed/28000738 http://dx.doi.org/10.1038/srep39598 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Gao, Ningning Zhong, Jingjing Wang, Xiaodong Jin, Zhenchao Li, Wang Liu, Yu Diao, Yuwen Wang, Zhulin Jiang, Wenqi Jin, Guangyi Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib |
title | Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib |
title_full | Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib |
title_fullStr | Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib |
title_full_unstemmed | Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib |
title_short | Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib |
title_sort | immunomodulatory and antitumor effects of a novel tlr7 agonist combined with lapatinib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175151/ https://www.ncbi.nlm.nih.gov/pubmed/28000738 http://dx.doi.org/10.1038/srep39598 |
work_keys_str_mv | AT gaoningning immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT zhongjingjing immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT wangxiaodong immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT jinzhenchao immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT liwang immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT liuyu immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT diaoyuwen immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT wangzhulin immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT jiangwenqi immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib AT jinguangyi immunomodulatoryandantitumoreffectsofanoveltlr7agonistcombinedwithlapatinib |